TABLE 2

PSA and Radiologic Response of All Patients as Grouped by Bone Scan Response

Patient no.	PSA baseline (ng/mL)	PSA follow-up evaluated at 12 wk^* (ng/mL)	PSA change (%)	Bone scan^*	CT scan notes^†
1	25	16.3	−35	CR	Stable disease (retroperitoneal nodes)
2	110.6	115	4	PR
3	460.8	1,620	252	PR	PD (new liver metastasis)
4	110.7	132.8	20	PR
5	598.9	592.4	−1	PR	Stable disease (pelvic mass and nodes)
6	311.1	966	211	PR	PD (new liver metastasis)
7	41.9	117.6	180	Stable disease	Stable disease (pulmonary metastasis)
8	33.5	90.9	171	Stable disease	PD (paraaortic nodes)
9	212.3	555.2	162	Stable disease
10	21.2	32.9	55	Stable disease
11	7.6	11	45	Stable disease
12	21	23	10	Stable disease
13	26	17.5	−33	Stable disease	Stable disease (pelvic nodes)
14	6.3	2.9	−54	Stable disease
15	17.6	6.3	−64	Stable disease	PR (retroperitoneal nodes)
16	29.8	135	353	PD	Stable disease (retroperitoneal nodes)
17	40.8	162.8	299	PD
18	388.1	1,412	264	PD	Stable disease (retroperitoneal nodes)
19	47	66.9	42	PD	Stable disease (retroperitoneal nodes)
20	135	162	20	PD	Stable disease (paraaortic nodes)
21	34.1	27.5	−20	PD
22	14.6	8.8	−40	PD
23	157	557.9	255	NE	Stable disease (retroperitoneal nodes)
24	28.4	77.1	172	NE	Stable disease (pelvic nodes)
25	283.9	251.4	−11	NE

↵* Evaluated at baseline and after 12 wk on study.
↵† CT scan was evaluated using RECIST; only soft-tissue lesions were considered. In subjects without definite evidence of soft-tissue disease, “CT scan notes” is left blank.
CR = complete response; PR = partial response; PD = progressive disease; NE = not evaluable.